Form 4: Neurogene Inc. CEO Rachel McMinn Acquires Stock Options
SEC Form 4 Filing
Neurogene Inc. CEO Rachel McMinn reports the acquisition of employee stock options.
Summary
- Rachel McMinn, CEO of Neurogene Inc., filed a Form 4 with the SEC.
- The filing reports the acquisition of 93,282 employee stock options on March 13, 2024, at an exercise price of $36.06.
- The options vest as to 1/4 on March 13, 2025, and then 1/48 monthly thereafter, contingent on continued service.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine filing indicating stock option grants, which can be seen as a positive sign of aligning management interests with shareholders, but it doesn't inherently indicate strong positive or negative sentiment.
Positives
- The acquisition of stock options by the CEO could be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.
Stakeholder Impact
- The acquisition of stock options by the CEO aligns her interests with those of the shareholders, potentially incentivizing her to increase shareholder value.
Key Dates
| Date | Description |
|---|---|
| 03/13/2024 | Date of transaction: Rachel McMinn acquired employee stock options. |
| 03/13/2025 | First vesting date: 1/4 of the total number of shares vest. |
| 03/13/2034 | Expiration date of the options. |
| 03/14/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.